Centene Corporation

NYSE:CNC Voorraadrapport

Marktkapitalisatie: US$28.5b

Centene Toekomstige groei

Future criteriumcontroles 3/6

Centene zal naar verwachting groeien in winst en omzet met respectievelijk 66.9% en 3.6% per jaar. De winst per aandeel zal naar verwachting groeien met 65.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 9.5% zijn.

Belangrijke informatie

66.9%

Groei van de winst

65.24%

Groei van de winst per aandeel

Healthcare winstgroei18.4%
Inkomstengroei3.6%
Toekomstig rendement op eigen vermogen9.53%
Dekking van analisten

Good

Laatst bijgewerkt22 May 2026

Recente toekomstige groei-updates

Recent updates

Narratiefupdate • May 16

CNC: Margin Recovery Efforts Will Offset Policy And Exchange Uncertainty

Centene's updated analyst price target moves from $43.47 to $54.94 as analysts factor in slightly higher revenue growth assumptions, a higher forward P/E multiple, and recent price target increases and upgrades across several research firms, balanced by some ongoing margin concerns. Analyst Commentary Recent research updates on Centene show a mix of optimism on the earnings and margin recovery path alongside caution about Medicaid and exchange exposure.
Narratiefupdate • Apr 29

CNC: Policy And Exchange Uncertainty Will Pressure Margins And Constrain Upside

Analysts have trimmed the fair value estimate for Centene to $43.47 from $44.18, reflecting updated views on revenue growth, margin potential, and a lower expected future P/E multiple, even as several recent price target revisions highlight ongoing debate around the stock. Analyst Commentary Recent Street research paints a mixed picture for Centene, with several firms adjusting price targets and ratings as they reassess the company after Q4 results, updated guidance, and regulatory developments.
Seeking Alpha • Apr 28

Centene: Big Comeback Story

Summary Centene Corporation delivered a strong Q1 earnings beat, signaling a robust turnaround after a challenging year for health insurers. Q1 revenue surged to $49.94 billion, up 7.1% year-over-year and $2.4 billion above consensus, driven by premium yield and Medicaid growth. Cost discipline was evident as the health benefits ratio fell to 87.3% and SG&A expenses declined, fueling a $1.24 adjusted EPS beat versus consensus. CNC raised 2026 revenue and EPS guidance, now projecting at least $3.40 adjusted EPS—a 63.4% year-over-year increase—supporting a bullish re-rating and buy recommendation. Read the full article on Seeking Alpha
Narratiefupdate • Apr 15

CNC: Medicaid Margins In 2026 Will Underpin Future Earnings Power

Centene's updated analyst price targets show only a modest reduction in implied fair value to about $60.51, as analysts factor in slightly better revenue growth and margins while tempering expectations with lower assumed P/E multiples and continued concern about margin pressure and exchange and Medicaid visibility. Analyst Commentary Recent research on Centene points to a mixed backdrop, but with a clear group of bullish analysts highlighting valuation support, execution on margins, and potential growth from policy and rate decisions.
Narratiefupdate • Apr 01

CNC: Government Program Margins In 2026 Will Support Future Earnings Power

Centene's updated analyst price targets show a modest downward reset of about $4 across several firms to a range of roughly $32 to $49, with analysts citing recalibrated valuation multiples, ongoing Medicaid and exchange visibility questions, and mixed readthroughs from recent Q4 results and policy headlines. Analyst Commentary Recent research shows a split view on Centene, with some firms trimming targets and others lifting them, but the common thread is a focus on how Medicaid, exchange membership, and Q4 execution shape the risk and reward profile from here.
Narratiefupdate • Mar 18

CNC: Government Managed Care Recovery In 2026 Will Support Future Earnings Power

Narrative Update Centene's implied fair value estimate has edged lower to about $60.89 from $62.81 as analysts recalibrated price targets. This reflects slightly softer growth and margin assumptions and a mix of recent target cuts and trims in valuation multiples across the group.
Narratiefupdate • Mar 04

CNC: Medicaid And Exchange Uncertainty Will Pressure Margins Despite 2026 EPS Guidance

Analysts have nudged their average price targets for Centene higher into a $43 to $59 range, pointing to margin improvement efforts, potential earnings power across segments, and sector recovery themes, even as they flag ongoing uncertainty around Medicaid and exchange visibility. Analyst Commentary Recent research on Centene shows a mix of optimism around margin potential and earnings power, alongside pointed concerns about execution risks in key government programs.
Narratiefupdate • Feb 17

CNC: Policy Uncertainty And Margin Recovery Prospects Will Shape Balanced Outlook

Analysts have lifted their average price target on Centene by about $3 to roughly $44, citing updated views on fair value, slightly higher expected profit margins and P/E, and ongoing research that points to potential margin recovery in government managed care despite recent CMS related concerns. Analyst Commentary Recent research on Centene reflects a mix of optimism around long term earnings power in government managed care and caution around policy and utilization risks that could affect how quickly that potential is realized.
Narratiefupdate • Feb 03

CNC: CMS Rate Pressure And Medicaid Uncertainty Will Restrain Future Earnings Recovery

Analysts have lifted their price targets on Centene into a US$43 to US$59 range, citing updated views on government managed care earnings potential and recently softer utilization trends, even as broader commentary highlights ongoing policy and Medicaid uncertainty for the sector. Analyst Commentary Recent research on Centene sits against a mixed backdrop for government managed care, with several firms highlighting both potential earnings recovery drivers and ongoing policy and contract risks.
Narratiefupdate • Jan 20

CNC: Government Managed Care Policy Tailwinds Will Support Future Earnings Power

Analysts have lifted their fair value estimate for Centene from about $54.65 to roughly $62.81, citing updated views on discount rates, revenue growth, margins, and future P/E following recent price target hikes and sector commentary around government managed care and the "Great Healthcare Plan." Analyst Commentary Bullish analysts are highlighting a mix of policy tailwinds, product positioning, and company specific execution as reasons to revisit Centene's valuation. Recent research focuses on how government managed care, Medicare Advantage rate discussions, and the "Great Healthcare Plan" could influence earnings power and the multiple investors are willing to pay.
Narratiefupdate • Jan 06

CNC: Marketplace Margin Recovery And Medicaid Pressures Will Shape Balanced Outlook

Analysts have raised their implied fair value estimate for Centene to about US$41 from roughly US$40, reflecting a mix of higher price targets tied to recent earnings beats and margin recovery expectations in Marketplace and Medicaid, partially balanced by concerns around Medicaid trends and contract losses. Analyst Commentary Recent Street research on Centene reflects a split view, with some analysts focusing on earnings power from margin recovery and others highlighting ongoing risks in Medicaid and selected contracts.
Narratiefupdate • Dec 19

CNC: Medicaid Margin Pressures Will Likely Cap Earnings Recovery Ahead

Analysts have raised their fair value estimate for Centene to $32 from $24, citing improving margin visibility, stronger than expected Q3 results, and a more constructive long term earnings trajectory despite near term Medicaid and contract headwinds. Analyst Commentary Street research following Centene's Q3 earnings has been mixed, with several firms lifting price targets on the back of stronger profitability trends while others caution that EPS visibility remains constrained by Medicaid and Marketplace uncertainties.
Narratiefupdate • Dec 05

CNC: Marketplace And Medicaid Margin Normalization Will Offset Policy And Contract Headwinds

Analysts have modestly raised their price target on Centene to $39.94 from $39.41, citing improved profit margin visibility and expectations for continued EPS growth as Marketplace and Medicaid margins recover, despite lingering near-term Medicaid pressures. Analyst Commentary Street research on Centene has become more polarized, with several bullish analysts lifting price targets into the mid 40s on the back of Q3 outperformance and clearer earnings visibility, while a cohort of more cautious voices highlight lingering Medicaid and Star rating risks that could constrain valuation multiple expansion.
Narratiefupdate • Nov 21

CNC: Margin Recovery In Medicaid And Marketplace Will Drive 2026 Earnings Upside

Centene's analyst price target has increased by $5.59 to $45.00, as analysts expect margin recovery in the Marketplace and Medicaid segments to drive accelerated earnings growth, despite ongoing near-term pressures. Analyst Commentary Recent research coverage of Centene highlights a mix of positive and negative outlooks, with analyst views divided over the company’s near- and medium-term trajectory.
Narratiefupdate • Nov 06

CNC: Medicaid Margin Stability And 26% ACA Premium Hike Will Shape 2026 Prospects

Centene’s analyst price target has been raised from $36 to approximately $39.76 per share. Analysts cite improving Medicaid profitability and stronger earnings guidance as key drivers for the upward revision.
Narratiefupdate • Oct 22

Analysts Lift Centene Price Target on Margin Recovery but Warn of Lasting Sector Headwinds

Centene's analyst fair value target has been increased from $34.63 to $36.00. Analysts highlight improving margin visibility and constructive EPS guidance updates as key factors supporting the upward revision.
Narratiefupdate • Oct 08

Medicaid And Medicare Advantage Will Expand Health Care Access

Centene's analyst price target increased from $33.94 to $34.63, as analysts cited stable EPS guidance, anticipated Medicaid margin improvement, and a constructive outlook for Marketplace rates as supporting factors for the revision. Analyst Commentary Recent analyst research on Centene reflects a full spectrum of perspectives, as experts weigh strong execution signals against ongoing uncertainties in the managed care and healthcare exchange landscape.
Narratiefupdate • Sep 19

Medicaid And Medicare Advantage Will Expand Health Care Access

Centene's modest price target increase reflects mixed analyst sentiment, with optimism around reaffirmed FY25 EPS guidance and Medicaid margin improvements tempered by concerns over ongoing Medicaid and marketplace pressures, regulatory risks, and reduced long-term earnings visibility, resulting in a slight upward revision of fair value to $33.94. Analyst Commentary Bullish analysts cite reaffirmation of FY25 adjusted EPS guidance and constructive commentary on Medicaid margin improvement, ACA Marketplace rate refiling, and Stars performance as supporting recent price target raises.
Analyseartikel • Sep 12

Centene Corporation's (NYSE:CNC) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Centene Corporation ( NYSE:CNC ) shareholders are no doubt pleased to see that the share price has bounced 30% in the...
Narratiefupdate • Sep 04

Medicaid And Medicare Advantage Will Expand Health Care Access

Centene’s analyst price target remains at $34.56 as ongoing macro and regulatory uncertainty, elevated Medicaid cost trends, and withdrawn 2025 EPS guidance have driven increased caution and reduced forward earnings visibility. Analyst Commentary Persistent macro uncertainty and regulatory volatility in the healthcare exchange (ACA Marketplace) and Medicaid markets are driving cautious outlooks, especially due to potential disenrollment, risk pool degradation, and rate/trend volatility stemming from legislative changes and the expiration of enhanced APTCs. Centene’s withdrawal of FY2025 EPS guidance, prompted by incorrect Marketplace risk-adjustment assumptions and elevated Medicaid cost trends, has resulted in significant downward revisions to earnings estimates for the next three years.
Analyseartikel • Jul 03

Why Investors Shouldn't Be Surprised By Centene Corporation's (NYSE:CNC) 38% Share Price Plunge

Unfortunately for some shareholders, the Centene Corporation ( NYSE:CNC ) share price has dived 38% in the last thirty...
Seeking Alpha • Mar 26

Centene: A Leader In Government-Sponsored Insurance And Its Prospects

Summary Centene's business transformation and strategic focus on core segments have led to increased operational marginality, despite losing 3.3 million Medicaid customers in 2024. I assign a "Buy" rating to Centene, with a fair valuation of $73 per share, indicating a 27% potential increase from the current price. The company’s competitive advantage lies in its focus on Medicaid and Medicare, but it faces risks from regulatory changes and strong competition. Centene's prospects are bolstered by demographic trends, Medicaid privatization, and ACA Marketplace demand, with expected improvements in cash flow and profitability. Read the full article on Seeking Alpha
Seeking Alpha • Mar 18

Centene Corporation Is Resilient And Will Thrive

Summary Centene Corporation is a buy opportunity under $60, with a strong valuation and momentum, despite market volatility and economic concerns. The company reported strong Q4 '24 results, with EPS of $0.80 and FY '24 EPS of $7.17, and management raised 2025 revenue guidance by $4 billion. Risks include potential Medicaid and Medicare enrollment cuts, program pullbacks, and cash flow concerns for the company, but we expect management to navigate these challenges. Insiders and hedge funds are investing, indicating confidence in Centene's resilience and growth potential, with a target price of around $72. Read the full article on Seeking Alpha
Seeking Alpha • Jan 02

Centene: Attractive Risk-Reward For A Growing Company At A Value Price

Summary Centene reported strong Q3’24 results, beating revenue expectations by $4.13 billion and achieving EPS of $1.62, driven by Medicaid rate increases and membership growth. Key highlights from the quarter include successful Medicaid reprocurements, improved 2025 Medicare Advantage star ratings, and advancements in AI for operational efficiency, positioning Centene for long-term growth. Despite some leverage, Centene's investment-grade rating and attractive debt maturities suggest financial stability, with a promising outlook for EPS growth and Medicare revenue. Insider buying and undervaluation, with Centene trading at around 10x earnings, indicate confidence in the company's future despite Medicaid redetermination and regulatory risks. Read the full article on Seeking Alpha
Seeking Alpha • Oct 22

Centene: Should Have Followed My Original Thesis, But A Buy For Q3 2024

Summary Centene, a leading health insurer, shows strong fundamentals and growth despite sector challenges, making it a "Buy" at a target price of $70/share. The company’s 2Q24 results indicate robust earnings growth and increasing membership, contrasting with peers like Humana, which face significant declines. Centene's valuation at $61/share with a P/E of 9x is attractive, projecting a potential 27.17% annualized upside until 2026. Despite lacking a dividend, Centene's stability and growth prospects in government programs and managed healthcare segments justify a conservative investment approach. Read the full article on Seeking Alpha

Winst- en omzetgroeiprognoses

NYSE:CNC - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2028197,9022,4862,5463,93511
12/31/2027190,8591,6361,6072,72014
12/31/2026190,3751,2222,7474,16414
3/31/2026178,332-6,4447,1127,944N/A
12/31/2025176,151-6,6744,3215,088N/A
9/30/2025167,285-5,2903,3564,064N/A
6/30/2025159,2682,0541,0801,730N/A
3/31/2025153,2443,4531,4922,120N/A
12/31/2024147,1453,305-490154N/A
9/30/2024146,3523,067245958N/A
6/30/2024144,2022,8232,2612,957N/A
3/31/2024142,9492,7352,6033,328N/A
12/31/2023141,3932,7027,2548,053N/A
9/30/2023139,3642,4445,4516,260N/A
6/30/2023138,1112,7137,6518,571N/A
3/31/2023136,9411,4838,3929,379N/A
12/31/2022135,9991,2025,2576,261N/A
9/30/2022132,7562,0147,4938,512N/A
6/30/2022129,2281,8605,9856,982N/A
3/31/2022124,1811,4974,3485,313N/A
12/31/2021118,5731,3473,2954,205N/A
9/30/2021114,1307365,6436,511N/A
6/30/2021111,2847202,8633,757N/A
3/31/2021108,1582,4614,9075,786N/A
12/31/2020104,2801,8084,6345,503N/A
9/30/202095,7642,0291,0081,871N/A
6/30/202086,5231,5561,9182,724N/A
3/31/202078,105845-804-73N/A
12/31/201970,8071,321N/A1,483N/A
9/30/201968,3851,353N/A1,500N/A
6/30/201965,5071,277N/A2,147N/A
3/31/201961,0281,082N/A704N/A
12/31/201856,688900N/A1,234N/A
9/30/201852,618889N/A2,318N/A
6/30/201848,6551,075N/A1,867N/A
3/31/201847,2011,029N/A2,087N/A
12/31/201745,810828N/A1,489N/A
9/30/201744,870853N/A2,631N/A
6/30/201743,646796N/A3,016N/A
3/31/201742,468713N/A2,903N/A
12/31/201637,693562N/A1,851N/A
9/30/201632,839416N/A460N/A
6/30/201628,062360N/A40N/A
3/31/201622,948277N/A809N/A
12/31/201521,292356N/A658N/A
9/30/201519,854350N/A827N/A
6/30/201518,548339N/A1,206N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat CNC de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 3.5% ).

Winst versus markt: Er wordt verwacht dat CNC de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat CNC binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van CNC ( 3.6% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 11.7% per jaar).

Hoge groei-inkomsten: De omzet van CNC ( 3.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen CNC zal naar verwachting over 3 jaar laag zijn ( 9.5 %).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/05/22 04:25
Aandelenkoers aan het einde van de dag2026/05/22 00:00
Inkomsten2026/03/31
Jaarlijkse inkomsten2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Centene Corporation wordt gevolgd door 34 analisten. 14 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
null nullArgus Research Company
Hua HaBaird
Andrew MokBarclays